Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-13

Clinical Trial Update: A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing milvexian to apixaban in adults with atrial fibrillation; the study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Apixaban (Eliquis) (apixaban)
  • Milvexian (milvexian)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Atrial Fibrillation | Phase 3 | Status: ACTIVE_NOT_RECRUITING